Skip to content

Replimune Group REPL Interest Paid

Interest Paid at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$10.4M-20.9%
Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
$2.78M+114%
CG Oncology logo
CG OncologyCGON
$47K+82.5%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$0
Arcus Biosciences logo
Arcus BiosciencesRCUS
$1.75M+600%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$20.12M+29.0%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+30.2%
Enterprise value$885.15M+30.0%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:InterestPaidNet.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's interest paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's interest paid?
Replimune Group (REPL) reported interest paid of $1.04M in Q4 2025.
How has Replimune Group's interest paid changed year-over-year?
Replimune Group's interest paid increased by 255.3% year-over-year, from $293K to $1.04M.
What does interest paid mean?
Supplemental disclosure of total cash interest paid on all debt and lease obligations during the period.